Seres Therapeutics Inc banner

Seres Therapeutics Inc
NASDAQ:MCRB

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
NASDAQ:MCRB
Watchlist
Price: 9.32 USD 2.08% Market Closed
Market Cap: $84.3m

Wall Street
Price Targets

MCRB Price Targets Summary
Seres Therapeutics Inc

Wall Street analysts forecast MCRB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MCRB is 21.42 USD with a low forecast of 20.2 USD and a high forecast of 23.1 USD.

Lowest
Price Target
20.2 USD
117% Upside
Average
Price Target
21.42 USD
130% Upside
Highest
Price Target
23.1 USD
148% Upside
Seres Therapeutics Inc Competitors:
Price Targets
ARDX
Ardelyx Inc
163% Upside
MGIC
Magic Software Enterprises Ltd
6% Upside
EOLS
Evolus Inc
180% Upside
HCAT
Health Catalyst Inc
107% Upside
AKTIA
Aktia Bank Abp
3% Upside
NN
NextNav Inc
24% Upside
QXO
SilverSun Technologies Inc
51% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MCRB's stock price target?
Price Target
21.42 USD

According to Wall Street analysts, the average 1-year price target for MCRB is 21.42 USD with a low forecast of 20.2 USD and a high forecast of 23.1 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett